

# Joshua F Zeidner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6708968/publications.pdf>

Version: 2024-02-01

82  
papers

1,464  
citations

471371

17  
h-index

345118

36  
g-index

85  
all docs

85  
docs citations

85  
times ranked

2547  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 60-69.	3.2	17
2	Genomic characteristics and prognostic significance of co-mutated <i>ASXL1</i> / <i>SRSF2</i> acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 462-470.	2.0	19
3	Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 97-111.	1.2	10
4	Prevalence of discordant QTc values among cancer patients by the Bazett, Fridericia, and Framingham formulae: Evidence for a standardized approach. <i>Journal of Clinical Oncology</i> , 2021, 39, 6575-6575.	0.8	0
5	INSIGHTS INTO ANTHRACYCLINE CARDIOTOXICITY: A CASE OF ACUTE EOSINOPHILIC MYOCARDITIS AFTER INDUCTION CHEMOTHERAPY WITH DAUNORUBICIN. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1904.	1.2	1
6	CD123-targeted therapy in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 561-576.	1.0	7
7	Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment. <i>Leukemia and Lymphoma</i> , 2021, 62, 3035-3038.	0.6	1
8	Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 245-257.	1.0	1
9	Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1021.e1-1021.e5.	0.6	15
10	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 616-629.	2.6	41
11	Bilineal evolution of a <i>U2AF1</i> -mutated clone associated with acquisition of distinct secondary mutations. <i>Blood Advances</i> , 2021, 5, 5612-5616.	2.5	0
12	Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. <i>Leukemia</i> , 2021, 35, 2119-2124.	3.3	74
13	A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 175.	2.8	3
14	Comprehensive Genomic Characterization of <i>ASXL1</i> C.1934dupG (p.G646fs*12) Versus Other <i>ASXL1</i> mutations in Myeloid Neoplasia. <i>Blood</i> , 2021, 138, 3466-3466.	0.6	0
15	Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains. <i>Journal of Geriatric Oncology</i> , 2021, . .	0.5	0
16	Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 173-177.	1.2	11
17	Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS. <i>Leukemia</i> , 2020, 34, 1563-1576.	3.3	17
18	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56

#	ARTICLE	IF	CITATIONS
19	Philadelphia Chromosomeâ€­positive Acute Myeloid Leukemia With <i>t(9;22)(p21;p21) BCR-ABL1</i> Fusion Transcript. <i>HemaSphere</i> , 2020, 4, e484.	1.2	4
20	MDS-336: Phase 2 Study of Pevonedistat + Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S323-S324.	0.2	2
21	Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1411-1413.	0.8	1
22	Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML. <i>Clinical Cancer Research</i> , 2020, 26, 4174-4176.	3.2	5
23	Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative. <i>Blood</i> , 2020, 136, 26-28.	0.6	2
24	Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (LB AML) (NCT02610777).. <i>Journal of Clinical Oncology</i> , 2020, 38, 7506-7506.	0.8	15
25	Acute Myeloid Leukemia: Changing Treatment Paradigms and Novel Agents in Development. <i>Current Cancer Drug Targets</i> , 2020, 20, 471-472.	0.8	2
26	Immune Checkpoint Inhibitors in AML-A New Frontier. <i>Current Cancer Drug Targets</i> , 2020, 20, 545-557.	0.8	5
27	Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm. <i>Blood</i> , 2020, 136, 48-50.	0.6	0
28	Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes. <i>Blood</i> , 2020, 136, 39-40.	0.6	4
29	Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 3-4.	0.6	0
30	Trials and Tribulations of Corrected QT Interval Monitoring in Oncology: Rationale for a Practice-Changing Standardized Approach. <i>Journal of Clinical Oncology</i> , 2019, 37, 2719-2721.	0.8	8
31	Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 989-1001.	1.9	43
32	Assessing Measurable Residual Disease in Acute Myeloid Leukemia. <i>Advances in Molecular Pathology</i> , 2019, 2, 45-58.	0.2	1
33	Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET). <i>Leukemia and Lymphoma</i> , 2019, 60, 2793-2797.	0.6	3
34	Myeloid sarcoma manifesting as generalized lymphadenopathy in a patient with myelofibrosis. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2274-2276.	0.2	0
35	Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150957.	0.7	6
36	Acute Myeloid Leukemia with Co-occurring Mutated <i>ASXL1</i> and <i>SRSF2</i> Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic Leukemia. <i>HemaSphere</i> , 2019, 3, e292.	1.2	10

#	ARTICLE	IF	CITATIONS
37	ASXL1/SRSF2 Co-Mutated Acute Myeloid Leukemia (AML): A Rare but Distinct Subpopulation with Dismal Outcomes. <i>Blood</i> , 2019, 134, 2598-2598.	0.6	1
38	Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML. <i>Blood</i> , 2019, 134, 831-831.	0.6	26
39	Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients. <i>Blood</i> , 2019, 134, 832-832.	0.6	47
40	A Signature of T Cell Exhaustion Is Enriched in the Bone Marrow (BM) of AML Patients and Shared with Immune Exhaustion Signatures of Solid Tumors. <i>Blood</i> , 2019, 134, 2711-2711.	0.6	0
41	Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 1417-1417.	0.6	2
42	Basic Drug Development With Structural Considerations. , 2019, , .		0
43	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. <i>Blood</i> , 2018, 131, 1415-1424.	0.6	160
44	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. <i>Clinical Cancer Research</i> , 2018, 24, 3519-3527.	3.2	80
45	A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e13-e18.	0.2	8
46	Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. <i>Nature Biomedical Engineering</i> , 2018, 2, 831-840.	11.6	220
47	Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment. <i>Leukemia and Lymphoma</i> , 2018, 59, 3010-3012.	0.6	2
48	Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7â€%+â€%3) in newly diagnosed high-risk acute myeloid leukemia (AML). <i>Leukemia Research</i> , 2018, 72, 92-95.	0.4	30
49	Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. <i>JCI Insight</i> , 2018, 3, .	2.3	123
50	Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 30-30.	0.6	7
51	Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML. <i>Blood</i> , 2018, 132, 4054-4054.	0.6	4
52	Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS). <i>Blood</i> , 2018, 132, 335-335.	0.6	0
53	A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7010-7010.	0.8	1
54	Immunomodulatory Drugs: IMiDs in Acute Myeloid Leukemia (AML). <i>Current Drug Targets</i> , 2017, 18, 304-314.	1.0	16

#	ARTICLE	IF	CITATIONS
55	Association of acute myeloid leukemias most immature phenotype with risk groups and outcomes. <i>Haematologica</i> , 2016, 101, 607-616.	1.7	21
56	Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	7
57	Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 98-98.	0.6	7
58	Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS). <i>Blood</i> , 2016, 128, 2820-2820.	0.6	0
59	Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, 1172-1179.	1.7	93
60	Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1312-1318.	0.4	94
61	The evolution of treatment strategies for patients with chronic myeloid leukemia relapsing after allogeneic bone marrow transplant: can tyrosine kinase inhibitors replace donor lymphocyte infusions?. <i>Leukemia and Lymphoma</i> , 2015, 56, 128-134.	0.6	20
62	Optimizing the management of relapsed chronic myeloid leukemia post-allogeneic bone marrow transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 3001-3002.	0.6	0
63	Lenalidomide-associated hemolytic anemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2717-2719.	0.6	2
64	A Comparison of Clofarabine-Based (GCLAC) and Cladribine-Based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML. <i>Blood</i> , 2015, 126, 1342-1342.	0.6	2
65	Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial. <i>Blood</i> , 2015, 126, 1666-1666.	0.6	12
66	Correlation of acute myeloid leukemia (AML) stem cell phenotype with cytogenetic/molecular features and prognosis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7000-7000.	0.8	0
67	A Single-Center Retrospective Analysis of a Pediatric Salvage Chemotherapy Regimen for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 4919-4919.	0.6	0
68	Immune Modulation with Pomalidomide after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 1351-1351.	0.6	1
69	Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 3849-3849.	0.6	0
70	The Impact of Time of Admission on the Delivery of Care and Outcomes in High Risk Patients with Acute Leukemia. <i>Blood</i> , 2015, 126, 4530-4530.	0.6	0
71	Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon- $\gamma$ (IFN) in newly diagnosed chronic myeloid leukemia (CML). <i>Leukemia Research</i> , 2014, 38, 886-890.	0.4	8
72	Reason for CPXcitement in AML. <i>Blood</i> , 2014, 123, 3211-3212.	0.6	3

#	ARTICLE	IF	CITATIONS
73	A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. <i>Haematologica</i> , 2014, 99, 672-678.	1.7	48
74	A Comprehensive Assessment of Phase 1 Clinical Trials in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2282-2282.	0.6	2
75	A multicohort trial of the safety and efficacy of the PD-1 inhibitor MK-3475 in patients with hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3116-TPS3116.	0.8	1
76	Randomized multicenter phase II trial of timed-sequential therapy with flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus 7+3 for adults with newly diagnosed acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7002-7002.	0.8	0
77	Characterization of Immune Evasion Mechanisms at Diagnosis and after Chemotherapy in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 1065-1065.	0.6	0
78	Randomized Phase II Trial of Timed-Sequential Therapy (TST) with Flavopiridol (Alvocidib), Ara-C and Mitoxantrone (FLAM) Versus 7+3 for Adults Ages 70 Years and Under with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 47-47.	0.6	18
79	The Tissue's the Issue. <i>American Journal of Medicine</i> , 2010, 123, 420-422.	0.6	1
80	Painless Jaundice. <i>American Journal of Medicine</i> , 2010, 123, 601-603.	0.6	1
81	Investigational Antiplatelet Drugs for the Treatment and Prevention of Coronary Artery Disease. <i>Cardiology in Review</i> , 2008, 16, 250-259.	0.6	6
82	Diagnosis and management of viral myocarditis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 450-464.	0.4	4